NCT04080635View on ClinicalTrials.gov

Therapeutic Drug Monitoring of Brodalumab in Psoriasis Patients (BIOLOPTIM-BRO)

NARecruitingINTERVENTIONAL
Enrollment

100

Participants

Timeline

Start Date

December 14, 2018

Primary Completion Date

December 31, 2024

Study Completion Date

December 31, 2024

Conditions
Psoriasis Vulgaris
Interventions
PROCEDURE

Venapuncture

Blood samples will be collected to determine the serum trough levels and anti-drug antibodies of brodalumab

OTHER

Patient questionnaires

The study participant will complete the Dermatology Quality of Life Index (DLQI) and EQ5D5L

Trial Locations (7)

3000

NOT_YET_RECRUITING

University Hospital, Leuven

8000

NOT_YET_RECRUITING

AZ Sint-Jan, Bruges

8820

NOT_YET_RECRUITING

AZ Delta Rembert, Torhout

9000

NOT_YET_RECRUITING

AZ Maria Middelares, Ghent

NOT_YET_RECRUITING

AZ Sint-Lucas, Ghent

RECRUITING

University Hospital of Ghent, Ghent

9990

NOT_YET_RECRUITING

Private Practice Dermatology, Maldegem

All Listed Sponsors
collaborator

KU Leuven

OTHER

collaborator

University Ghent

OTHER

lead

University Hospital, Ghent

OTHER